Is there any predictive factor of the clinical response to IL2 therapy in metastatic malignant melanoma (Meeting abstract).

Important note: Information in this article was accurate in 1994. The state of the art may have changed since the publication date.

Is there any predictive factor of the clinical response to IL2 therapy in metastatic malignant melanoma (Meeting abstract).

Fourth International Congress on Anti-cancer Chemotherapy. February 2-5, 1993, Paris, France, p. 99, 1993.. Unique Identifier : AIDSLINE ICDB/94697771
Soubrane C; Mouawad R; Ichen M; Suissa J; Vuillemin E; Borel C; Benhammouda A; Weil M; Khayat D; Oncology Medical Lab., Salpetriere Hosp., 75013 Paris, France

Abstract: Immunological parameters following chemo-immunotherapy combination were studied in 31 patients with metastatic malignant melanoma. They received cisplatin (100 mg/m2) at day 1 and 28, r-interleukin-2 (IL2, Eurocetus) in continuous infusion from day 3-6, 17-21, 31-34 and 45-49. Alpha interferon (Roche) was given sc three times weekly. No significant change in CD4/CD8 ratio both at onset or during treatment was observed between responder (n = 19) and nonresponder (n = 11) patients. Regarding IL2 receptor study, the percentage of cells expressing TAC (p55) receptor did not change either between healthy volunteers (n = 20) and patients before any therapy or between responder and nonresponder patients. Concerning soluble IL2R shedding before any therapy, we observed a significant increase (p = 0.001) in patients (79 +/- 40 PM) compared to healthy donors (30.6 +/- 15 PM) but no significant variation was seen between responder and nonresponder patients. In contrast, during the treatment, the soluble IL2R ratio increased in both groups but, interestingly a significant difference was found between responder and nonresponder patients from day 7 (p less than 0.05) to day 21 (p less than 0.01) suggesting that the cells from nonresponder may be slower in becoming stimulated. It is the most striking point of our study since sIL2R might be an early predictive factor of the clinical response as obtained by logistic regression (p = 0.0063).Therefore patients with a soluble IL2R level greater than 250 PM have 12-fold more chances to present a clinical response.

Keywords: Cisplatin/*ADMINISTRATION & DOSAGE CD4-CD8 Ratio Human Interferon-alpha/THERAPEUTIC USE Interleukin-2/*ADMINISTRATION & DOSAGE Melanoma/DRUG THERAPY/METABOLISM/PATHOLOGY/*THERAPY Receptors, Interleukin-2/METABOLISM ABSTRACT
940630
M9460922

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1994. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1994. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .